Boya Bio-Pharmaceutical, a cornerstone of China’s specialized blood products sector, is facing a severe financial reckoning. Despite a healthy 18.7% increase in annual revenue to 2.06 billion RMB in 2025, the company’s net profit plummeted by a staggering 71.6%, falling to just 113 million RMB. The divergence between top-line growth and bottom-line collapse highlights a perilous period for the China Resources-backed entity.
The primary culprit for this fiscal anemia is a failed bet on the medical aesthetics market. Following the acquisition of Green Cross Hong Kong in late 2024, Boya was forced to record a 300 million RMB impairment charge related to its hyaluronic acid business. As China’s once-frenzied medical beauty sector cooled, the intangible assets and goodwill associated with the deal turned from strategic advantages into heavy liabilities.
Beyond the write-downs, Boya’s core blood products business is grappling with the harsh realities of China's healthcare reform. National policies including expanded Volume-Based Procurement (VBP) and the implementation of DRG/DIP hospital payment systems have squeezed margins. These cost-control measures, designed to stabilize the national insurance fund, have directly reduced clinical prescription volumes and intensified market competition for plasma-derived therapies.
Adding to the uncertainty is a leadership vacuum at the highest level. CEO Ren Hui, a veteran of the state-owned China Resources conglomerate and former vice president of Dong-E-E-Jiao, resigned in early 2026 after only nine months in office. His abrupt departure underscores the integration challenges and strategic friction that often plague high-profile mergers within the domestic pharmaceutical landscape.
In an attempt to right the ship, Boya has divested non-core assets, including an 80% stake in its subsidiary Boya Xinhe, to refocus on its plasma operations. The company is now pivoting toward "smart manufacturing" and operational efficiency to preserve its remaining market share. However, with demand softening and regulatory pressure mounting, the road to recovery for this industry leader remains fraught with structural obstacles.